alexa [Toxicity associated to efavirenz in HIV-infected persons enrolled in an expanded access program].
Infectious Diseases

Infectious Diseases

Journal of AIDS & Clinical Research

Author(s): Dona C, Soriano V, Barreiro P, JimnezNchera I, GonzlezLahoz J, Dona C, Soriano V, Barreiro P, JimnezNchera I, GonzlezLahoz J

Abstract Share this page

Abstract BACKGROUND: Efavirenz (EFV) is one of the latest antiretroviral compounds appeared in the market. Its toxicity profile is not well known. PATIENTS AND METHODS: The rate of adverse events was examined in 250 subjects enrolled in the expanded access program in a single institution located in Madrid, Spain. RESULTS: Adverse events grade >= 2 (WHO) were recorded in 33 (13.2\%) persons. The most common were neuropsychiatric disorders (8.4\%), cutaneous lesions (3.2\%), and gastrointestinal problems (0.8\%). The drug needed to be discontinued in 17 (6.8\%) patients. CONCLUSION: The rate of adverse events grade moderate-to-severe in patients receiving EFV is relatively low (13. 4\%), without evidence of cross-toxicity (i.e., rash by nevirapine). Neuropsychiatric and dermatological conditions are the most common, and ten to resolve spontaneously in two
This article was published in Med Clin (Barc) and referenced in Journal of AIDS & Clinical Research

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version